[EN] CATALYTIC DISPROPORTIONATION AND CATALYTIC REDUCTION OF CARBON-CARBON AND CARBON-OXYGEN BONDS OF LIGNIN AND OTHER ORGANIC SUBSTRATES<br/>[FR] DISMUTATION CATALYTIQUE ET RÉDUCTION CATALYTIQUE DES LIAISONS CARBONE-CARBONE ET CARBONE-OXYGÈNE DE LA LIGNINE ET AUTRES SUBSTRATS ORGANIQUES
申请人:UNIV CALIFORNIA
公开号:WO2011003029A2
公开(公告)日:2011-01-06
The present invention provides methods and catalyst compositions for the catalytic reduction of carbon-oxygen bonds of organic substrates and the catalytic disproportionation of carbon-oxygen or carbon-carbon bonds of organic substrates. These methods and catalyst compositions may be used to depolymerize lignin. The disproportionation of carbon-oxygen or carbon-carbon bonds of organic substrates or lignin is carried out by cleaving a carbon-oxygen bond or a carbon-carbon bond in a catalytic disproportionation reaction. The catalysts may be formed from a metal precursor such as ruthenium or vanadium and a bidentate ligand The catalytic reduction of carbon-oxygen bonds of organic substrates such as lignin is carried out by cleaving a carbon-oxygen bond in the presence of a hydrogen atom source. Lignin fragments produced following depolymerization by such methods may be further processed into fuels.
[EN] PHARMACEUTICALLY ACTIVE COMPOUNDS AS DAG-LIPASE INHIBITORS<br/>[FR] COMPOSÉS PHARMACEUTIQUEMENT ACTIFS À TITRE D'INHIBITEURS DE LIPASES DAG
申请人:UNIV LEIDEN
公开号:WO2016188972A1
公开(公告)日:2016-12-01
The present invention relates to novel compounds which are selective inhibitors of diacylglycerol lipase alpha and beta. These compounds are suitable for the treatment or prevention of disorders associated with, accompanied by or caused by increased 2-arachidonoylglycerol levels. Diacylglycerol lipase-a (alternative name: Snl-specific diacylglycerol hydrolase a; DAGL-a) and -β are enzymes responsible for the biosynthesis of the endocannabinoid 2-arachidonoylglycerol. Selective and reversible inhibitors are required to study the function of DAGLs in neuronal cells in an acute and temporal fashion. The inventive compounds are in particular suitable for the treatment of neurodegenerative diseases, inflammatory diseases, drug abuse and impaired energy balance, such as obesity, wherein X1 is -CH-, -CF- or -N-.
PHARMACEUTICALLY ACTIVE COMPOUNDS AS DAG-LIPASE INHIBITORS
申请人:Universiteit Leiden
公开号:EP3095787A1
公开(公告)日:2016-11-23
The present invention relates to novel compounds which are highly selective inhibitors of diacylglycerol lipase α and β. These compounds are suitable for the treatment or prevention of disorders associated with, accompanied by or caused by increased 2-arachidonoylglycerol levels. Diacylglycerol lipase-α (alternative name: Sn1-specific diacylglycerol hydrolase a; DAGL-α) and -β are enzymes responsible for the biosynthesis of the endocannabinoid 2-arachidonoylglycerol. Selective and reversible inhibitors are required to study the function of DAGLs in neuronal cells in an acute and temporal fashion. The inventive ompounds are in particular suitable for the treatment of neurodegenerative diseases, inflammatory diseases, drug abuse and impaired energy balance, such as obesity.